Clinical Trial: Study to Characterise Pharmacokinetics (PK), Pharmacodynamics (PD), and Safety of Anifrolumab Administered Subcutaneously (SC) or Intravenously (IV)

U.S., July 8 -- ClinicalTrials.gov registry received information related to the study (NCT07688980) titled 'Study to Characterise Pharmacokinetics (PK), Pharmacodynamics (PD), and Safety of Anifrolumab Administered Subcutaneously (SC) or Intravenously (IV)' on June 30.

Brief Summary: The purpose of this study is to assess the PK, PD, and safety of anifrolumab as SC administration or IV infusion in adult participants with systemic lupus erythematosus (SLE).

Study Start Date: Oct. 30, 2026

Study Type: INTERVENTIONAL

Condition: Systemic Lupus Erythematosus

Intervention: COMBINATION_PRODUCT: Anifrolumab: SC formulation via AI

Anifrolumab will be administered subcutaneously via an AI.

COMBINATION_PRODUCT: Anifrolumab: IV formulation

An...